Breaking News Instant updates and real-time market news.

ABT

Abbott

09:29
10/19/16
10/19
09:29
10/19/16
09:29

Abbott sees Q4 adjusted EPS of 64c-66c, consensus 65c

Abbott sees operational sales growth of mid single digits in the fourth quarter. For established pharmaceuticals, Abbott sees high-single-digit sales growth in Q4. In nutrition, Abbott sees Q4 sales growth similar to the third quarter. In diagnostics, Abbott sees mid-single-digit growth in Q4. In medical devices: for vascular Abbott sees mid-single-digit sales growth; in diabetes care, sees double-digit sales growth; in medical optics, sees low- to mid-single-digit sales growth. Guidance issued earlier on Q3 earnings call.

  • 19

    Oct

  • 21

    Oct

  • 06

    Nov

ABT Abbott

09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.

TODAY'S FREE FLY STORIES

EEM

MSCI Emerging Markets Index

$50.03

0.06 (0.12%)

06:41
01/19/18
01/19
06:41
01/19/18
06:41
Technical Analysis
MSCI Emerging Markets Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APPN

Appian

$36.15

-2.28 (-5.93%)

06:41
01/19/18
01/19
06:41
01/19/18
06:41
Downgrade
Appian rating change  »

Appian downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EWW

iShares MSCI Mexico

$52.62

0.38 (0.73%)

06:41
01/19/18
01/19
06:41
01/19/18
06:41
Technical Analysis
iShares MSCI Mexico: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$37.30

-0.76 (-2.00%)

06:40
01/19/18
01/19
06:40
01/19/18
06:40
Hot Stocks
Synchrony CEO: Substantial progress made on strategic priorities »

"Substantial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

UUP

PowerShares DB US Dollar Index Up

$23.61

-0.03 (-0.13%)

06:40
01/19/18
01/19
06:40
01/19/18
06:40
Technical Analysis
PowerShares DB US Dollar Index Up: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXN

Texas Instruments

$116.41

-2.75 (-2.31%)

06:40
01/19/18
01/19
06:40
01/19/18
06:40
Recommendations
Texas Instruments analyst commentary  »

Texas Instruments price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

NOV

National Oilwell

$37.91

-1.01 (-2.60%)

06:40
01/19/18
01/19
06:40
01/19/18
06:40
Hot Stocks
National Oilwell sees Q4 results at or above prior expectations »

National Oilwell Varco…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

UDN

PowerShares DB US Dollar Index Down

$22.78

0.03 (0.13%)

06:39
01/19/18
01/19
06:39
01/19/18
06:39
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$37.30

-0.76 (-2.00%)

06:39
01/19/18
01/19
06:39
01/19/18
06:39
Hot Stocks
Synchrony reports Q4 net interest margin 16.24% compared to 16.26% last year »

Return on assets was 1.6%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

PB

Prosperity Bancshares

$74.26

-0.2 (-0.27%)

06:38
01/19/18
01/19
06:38
01/19/18
06:38
Hot Stocks
Prosperity Bancshares announces stock repurchase program »

Prosperity Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 30

    Jan

ACOR

Acorda Therapeutics

$25.00

0.25 (1.01%)

, BIIB

Biogen

$344.44

-0.43 (-0.12%)

06:38
01/19/18
01/19
06:38
01/19/18
06:38
Periodicals
Biogen among companies weighing bids for Acorda, Bloomberg reports »

Biogen (BIIB) and…

ACOR

Acorda Therapeutics

$25.00

0.25 (1.01%)

BIIB

Biogen

$344.44

-0.43 (-0.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Mar

SYF

Synchrony

$37.31

-0.75 (-1.97%)

06:38
01/19/18
01/19
06:38
01/19/18
06:38
Hot Stocks
Synchrony reports estimated Common Equity Tier 1 ratio 16% »

The estimated Common…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

MRK

Merck

$61.13

-0.9 (-1.45%)

, AZN

AstraZeneca

$35.07

-0.01 (-0.03%)

06:36
01/19/18
01/19
06:36
01/19/18
06:36
Hot Stocks
Merck, AstraZeneca: LYNPARZA receives approval in Japan »

AstraZeneca (AZN) and…

MRK

Merck

$61.13

-0.9 (-1.45%)

AZN

AstraZeneca

$35.07

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 02

    Feb

  • 08

    Feb

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 23

    Oct

GWR

Genesee & Wyoming

$81.57

0.18 (0.22%)

06:36
01/19/18
01/19
06:36
01/19/18
06:36
Hot Stocks
Genesee & Wyoming reports December traffic 255,199 carloads, down 5,7% y/y »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

SYF

Synchrony

$37.30

-0.76 (-2.00%)

06:34
01/19/18
01/19
06:34
01/19/18
06:34
Hot Stocks
Synchrony reports Q4 net interest income up 8% to $3.9B »

Loan receivables grew $6…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

FHN

First Horizon

$20.21

-0.09 (-0.44%)

06:34
01/19/18
01/19
06:34
01/19/18
06:34
Earnings
First Horizon reports Q4 EPS (20c) may not compare with consensus 30c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

AZN

AstraZeneca

$35.07

-0.01 (-0.03%)

06:34
01/19/18
01/19
06:34
01/19/18
06:34
Periodicals
AstraZeneca sees big productivity jump amid fewer drug projects, Reuters reports »

AstraZeneca has seen an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 08

    Feb

  • 08

    Mar

  • 23

    Apr

WIT

Wipro

$5.77

-0.11 (-1.87%)

06:33
01/19/18
01/19
06:33
01/19/18
06:33
Earnings
Breaking Earnings news story on Wipro »

Wipro sees Q4 IT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIT

Wipro

$5.77

-0.11 (-1.87%)

06:33
01/19/18
01/19
06:33
01/19/18
06:33
Earnings
Wipro reports Q3 revenue $2.1B, consensus $2.1B »

IT Services Segment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFG

Citizens Financial

$45.76

-0.08 (-0.17%)

06:33
01/19/18
01/19
06:33
01/19/18
06:33
Hot Stocks
Breaking Hot Stocks news story on Citizens Financial »

Citizens Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

JAPAF

Japan Tobacco

$32.91

-0.29 (-0.87%)

06:33
01/19/18
01/19
06:33
01/19/18
06:33
Upgrade
Japan Tobacco rating change  »

Japan Tobacco upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFG

Citizens Financial

$45.76

-0.08 (-0.17%)

06:32
01/19/18
01/19
06:32
01/19/18
06:32
Hot Stocks
Citizens Financial raises quarterly dividend 22% to 22c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

PM

Philip Morris

$105.07

-0.72 (-0.68%)

, MO

Altria Group

$70.03

-0.12 (-0.17%)

06:31
01/19/18
01/19
06:31
01/19/18
06:31
Upgrade
Philip Morris, Altria Group, British American Tobacco rating change  »

Philip Morris upgraded to…

PM

Philip Morris

$105.07

-0.72 (-0.68%)

MO

Altria Group

$70.03

-0.12 (-0.17%)

BTI

British American Tobacco

$68.56

-0.82 (-1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 01

    Feb

CFG

Citizens Financial

$45.76

-0.08 (-0.17%)

06:31
01/19/18
01/19
06:31
01/19/18
06:31
Earnings
Citizens Financial reports Q4 EPS $1.35 with items, consensus 67c »

Reports Q4 revenue $1.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

SYF

Synchrony

$37.30

-0.76 (-2.00%)

06:30
01/19/18
01/19
06:30
01/19/18
06:30
Earnings
Breaking Earnings news story on Synchrony »

Synchrony reports Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.